Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

111.94
Delayed Data
As of 4:00pm ET
 -0.02 / -0.02%
Today’s Change
94.28
Today|||52-Week Range
126.07
+8.98%
Year-to-Date
The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November
12:58pm / MotleyFool.com - Paid Partner Content
Have Traders in Johnson & Johnson Recently Turned Bullish?
Nov 29 / TheStreet.com - Paid Partner Content
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nx...
10:02am / Zacks.com - Paid Partner Content
Big Pharma healthcare R&D steps out into the open
Nov 29 / FT.com - Paid Partner Content
Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
7:45am / TheStreet.com - Paid Partner Content
Frontrunning: November 29
Nov 29 / Investing Channel - Paid Partner Content
5 Things You Must Know Before the Market Opens Monday
6:07am / TheStreet.com - Paid Partner Content
Global Stocks Pressured As Oil Slides On OPEC Deal Concerns; US Futures, Dollar Rise
Nov 29 / Investing Channel - Paid Partner Content
Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
Dec 04 / TheStreet.com - Paid Partner Content
Actelion Shares Fall Sharply on Report it is Resisting $17 billion J&J Takeover
Nov 29 / TheStreet.com - Paid Partner Content
US corporate bonds: The weight of debt
Dec 04 / FT.com - Paid Partner Content
European Stocks Mixed, Oil Falls as OPEC Deal Hopes Fade
Nov 29 / TheStreet.com - Paid Partner Content
J&J Plans to Appeal Staggering $1B Judgment Against Hip Implant
Dec 03 / TheStreet.com - Paid Partner Content
Actelion weighs complicated deal to combine with part of J&J
Nov 28 / FT.com - Paid Partner Content
Forget Pfizer: Here Are 3 Better Dividend Stocks
Dec 02 / MotleyFool.com - Paid Partner Content
Actelion: independent thinking
Nov 28 / FT.com - Paid Partner Content
MedTech Sails Through Macro Woes: Stocks in Focus
Dec 02 / Zacks.com - Paid Partner Content
Stock Market News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Ro...
Dec 02 / Zacks.com - Paid Partner Content
Company News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
3 Small-Cap Biotech Stocks That Could Double in 2017
Dec 02 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALI...
Nov 28 / Zacks.com - Paid Partner Content
Frontrunning: December 2
Dec 02 / Investing Channel - Paid Partner Content
J&J (JNJ) Confirms it Approached Actelion for Possible Deal
Nov 28 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytr...
Dec 02 / Zacks.com - Paid Partner Content
3 Predictions for Intuitive Surgical in 2017
Nov 27 / MotleyFool.com - Paid Partner Content
5 Things You Must Know Before the Market Opens Friday
Dec 02 / TheStreet.com - Paid Partner Content
Trump's Presidency: The Worst Thing Investors Can Do Now
Nov 26 / MotleyFool.com - Paid Partner Content
MedTech Industry Stock Outlook - December 2016
Dec 01 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: Nike Raises Dividend, Boeing-Textron JV Bags Defense Contract
Nov 25 / Zacks.com - Paid Partner Content
Here's the Best Dividend Stock in Big Pharma
Dec 01 / MotleyFool.com - Paid Partner Content
J&J confirms talks with Actelion over pharma deal
Nov 25 / FT.com - Paid Partner Content
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
Dec 01 / Zacks.com - Paid Partner Content
J&J (JNJ) Reportedly Approaches Actelion for Acquisition
Nov 25 / Zacks.com - Paid Partner Content
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
Dec 01 / Zacks.com - Paid Partner Content
4 Perfect Healthcare Stocks for Investors in Their 50s
Nov 25 / MotleyFool.com - Paid Partner Content
If You're in Your 70s, Consider Buying These 2 Stocks
Dec 01 / MotleyFool.com - Paid Partner Content
Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov 25 / Zacks.com - Paid Partner Content
Is an Actelion Deal Good for Johnson & Johnson Shareholders?
Nov 30 / MotleyFool.com - Paid Partner Content
Lilly's Alzheimer Drug Fails Phase III Study, Stock Down
Nov 24 / Zacks.com - Paid Partner Content
Quest to cure Alzheimer's disease exhibits symptoms of failure
Nov 30 / FT.com - Paid Partner Content
In Your 60s? 2 Dividend Stocks You Might Want to Buy
Nov 22 / MotleyFool.com - Paid Partner Content
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
Nov 30 / Zacks.com - Paid Partner Content
Aduro Reports Partial Hold Lift on LADD Studies in U.S.
Nov 22 / Zacks.com - Paid Partner Content
Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion
Nov 30 / MotleyFool.com - Paid Partner Content
J&J Immunotherapy Darzalex OK'd for Label Expansion by FDA
Nov 22 / Zacks.com - Paid Partner Content
Report: Johnson & Johnson Boosts Bid For Actelion
Nov 29 / Investing Channel - Paid Partner Content
Nothing is cheap, says the investment house hoarding cash
Nov 15 / FT.com - Paid Partner Content
European Stocks Book Gains, Oil Slump Holds Down FTSE 100
Nov 29 / TheStreet.com - Paid Partner Content
Tech groups may bring cash piles home under Trump
Nov 09 / FT.com - Paid Partner Content